Autochthonous mouse models for prostate cancer: Past, present and future

Seminars in Cancer Biology

Volumn 11, Issue 3, 2001, Pages 245-259

  Huss, Wendy J ^a   Maddison, Lisette A ^a   Greenberg, Norman M ^a,b  

^a Department of Molecular and Cellular Biology ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Metastasis; Mouse models; Probasin; Prostate cancer; TRAMP

Indexed keywords

PROBASIN;

CANCER GROWTH; CANCER MODEL; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CARCINOGENESIS; METASTASIS; NONHUMAN; PREVALENCE; PROSTATE CANCER; REVIEW;

EID: 0034941823     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0373     Document Type: Article

References (139)

1. Carcinoma of prostate: Case against immediate hormonal therapy
2. Hormonal therapy in the management of prostate cancer: From Huggins to the present
3. Prostatic intraepithelial neoplasia: Animal models 2000
4. Workgroup I: Rodent models of prostate cancer
5. Workgroup 3: Transgenic and reconstitution models of prostate cancer
6. Studying cancer in the mouse
7. Molecular genetics of prostate cancer [in process citation]
8. Mouse models of prostate cancer
9. Prostate cancer in a transgenic mouse
10. Cell alterations induced by the large T-antigens of SV40 and polyoma virus
11. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation
12. Metastatic prostate cancer in a transgenic mouse
13. Pathologic progression of autochthonous prostate cancer in the TRAMP model
14. Androgen-independent prostate cancer progression in the TRAMP model
15. Prostatic steroid-binding protein. Isolation and characterization of C3 genes
16. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene
17. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: Histopathological and molecular biological alterations
18. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer
19. Cryptdins: Endogenous antibiotic peptides of small intestinal Paneth cells
20. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
21. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice
22. Prostate cancer progression, metastasis, and gene expression in transgenic mice
23. RasT24 driven by a probasin promoter induces prostatic hyperplasia in transgenic mice
24. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein
25. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia
26. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)-TGF-beta type II dominant negative receptor
27. Abnormal prostate development in C3(1)-bcl-2 transgenic mice
28. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo
29. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice
30. Analysis of the control of expression and tissue specificity of the keratin 5 gene, characteristic of basal keratinocytes. Fundamental role of an AP-1 element
31. Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells
32. Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development
33. Genomic instability-based transgenic models of prostate cancer
34. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
35. The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers
36. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
37. Mutation and expression analysis of the putative prostate tumonr-suppressor gene PTEN
38. Roles for Nkx3.1 in prostate development and cancer
39. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer
40. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers
41. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer
42. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression [in process citation]
43. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas
44. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas
45. Allelic loss on chromosome 13q in human prostate carcinoma
46. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue [in process citation]
47. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma
48. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade
49. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells
50. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3
51. Expression of MXI1, a Myc antagonist, is regulated by Sp1 and AP2
52. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth
53. Mutation of the MXI1 gene in prostate cancer
54. Point mutations of the Mxi1 gene are rare in prostate cancers
55. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer
56. Myc-enhanced expression of Cull promotes ubiquitin-dependent proteolysis and cell cycle progression
57. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer
58. Origin and development of carcinoma in the prostate
59. Cancer volume and site of origin of adenocarcinoma in the prostate: Relationship to local and distant spread
60. The endocrinology and developmental biology of the prostate
61. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia
62. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging
63. Histologic grading of prostate cancer: A perspective
64. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue
65. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
66. Prostate cancer: Molecular biology of early progression to androgen independence
67. Primary structure of a human glandular kallikrein gene
68. The combination of human glandular kallikrein and free prostate- specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderate y increased total PSA
69. Expression of the prostate-specific membrane antigen
70. Prostate-specific membrane antigen (PSMA): Current benefits and future value
71. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells
72. Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for factor VIII-related antigen and CD34 antigen)
73. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
74. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
75. An analysis of microvessel density, androgen receptor, p53, and HER-2/neu expression and gleason score in prostate cancer
76. VEGF Overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms
77. Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate
78. Keratin immunoreactivity in the benign and neoplastic human prostate
79. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate
80. Cell-cell interaction in prostate gene regulation and cytodifferentiation
81. Neuroendocrine cells in tumour growth of the prostate
82. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications
83. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis
84. Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle
85. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily
86. NYK/FLK-1: A putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo
87. On target with tumor blood vessel markers
88. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse
89. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact
90. What might a stromal response mean to prostate cancer progression
91. A transgenic mouse prostate cancer model
92. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer [in process citation]
93. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
94. Survey ofgene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
95. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
96. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer
97. Telomerase activity: A prevalent marker of malignant human prostate tissue
98. Peptide growth factors and prostate cancer: New models, new opportunities
99. Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model
100. Dysregulated expression of growth factors and their receptors in the development of prostate cancer
101. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
102. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells
103. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: Implication as a tumor suppressor
104. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression
105. c-met proto-oncogene expression in benign and malignant human prostate tissues
106. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
107. Overcoming bcl-2- and p53-mediated resistance in prostate cancer
108. p53 is mutated in a subset of advanced-stage prostate cancers
109. p53 oncogene mutations in human prostate cancer specimens
110. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer
111. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy
112. p53 expression and clinical outcome in prostate cancer
113. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and alIelotyping
114. Distant metastases from prostatic carcinoma express androgen receptor protein
115. Androgen receptors in endocrine-therapy-resistant human prostate cancer
116. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone
117. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
118. Cre recombinase: The universal reagent for genome tailoring
119. High-efficiency deleter mice show that FLPe is an alternative to CreloxP
120. Prostate specific expression of Cre recombinase in transgenic mice
121. Inducible site-specific recombination in the brain
122. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: Comparison of the recombinase activity of the tamoxifen- inducible Cre-ER(T) and Cre-ER(T2) recombinases
123. Flipping the oncogene switch: Illumination of tumor maintenance and regression
124. Transgenic animals with inducible, targeted gene expression in brain
125. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and upregulation of TGFalpha expression in transgenic mice
126. Streptogramin-based gene regulation systems for mammalian cells
127. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen
128. Early castration reduces prostatic carcinogenesis in transgenic mice
129. Visualizing gene expression by whole-body fluorescence imaging [in process citation]
130. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases
131. Visualizing the kinetics of tumor-cell clearance in living animals
132. PET imaging of transgene expression [in process citation]
133. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer)
134. E-7869 (R-flurbiprofen) inhibits progresion of prostate cancer in the TRAMP mouse
135. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
136. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
137. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
138. Ghemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice